Compliance · State rules

Office-use compounding in Wyoming

Expressly invalid for a pharmacy, in those words; the same two words are compulsory on an outsourcing facility’s label

USPeptideRx EditorialLast reviewed: August 31, 2026

Wyoming states the prohibition in the rule’s own words and then, a few chapters later, requires an outsourcing facility to print the same two words on its label. A prescription may not be dispensed to a practitioner on an order that is not issued for one specific patient, and a prescription order for "office use" is not a valid order — that is the pharmacy side. An outsourcing facility must label its compounded drugs with a statement that they are a compounded drug for office use only — that is the other side. Nowhere in this file is the routing of office stock away from pharmacies and toward outsourcing facilities put more plainly. Two further things a reader needs: Wyoming repealed both of its compounding chapters on 19 August 2025, and the express permission to supply practitioners died with them; and the Board’s own website says the outsourcing-facility licence class does not exist while its in-force rules create it and price it.

The governing rule

Wyoming’s office-use position is set by Wyo. Bd. of Pharmacy Rules ch. 2 § 6(d), with ch. 8 § 7. The text below is quoted verbatim; everything outside a quote block is our summary of it, and the two are kept visually separate on purpose.

Wyo. Bd. of Pharmacy Rules ch. 2 § 6(d) (Ref. No. 059.0001.2.05242023) — the prohibition, by name

A prescription may not be dispensed to a practitioner based on an order that is not issued for one specific patient. A prescription order for "office use" is not a valid order.

Wyo. Bd. of Pharmacy Rules ch. 8 § 7(e)(iv)(C) (Ref. No. 059.0001.8.08192025) — the label an outsourcing facility must carry

The following or similar statement: "This is a compounded drug. For office use only" or "Not for resale;" and

Wyo. Bd. of Pharmacy Rules ch. 8 § 7(b) — the licence class the rules create

Resident and non-resident outsourcing facilities shall be licensed as such in this State and annually renew their licensure.

Wyoming State Board of Pharmacy, "503B Outsourcing Facilities" — the Board’s own page, which says the opposite

The Wyoming State Board of Pharmacy does not yet have a separate license type for Outsourcing Facilities. We are in the process of creating this new license type, however, it may be some time before the process is complete.

Wyo. Bd. of Pharmacy Rules ch. 13 § 3(d) — REPEALED 19 August 2025. Quoted as repealed law, not as authority

Pharmacists shall not offer compounded medications to other pharmacies or licensed entities for resale; except pharmacists may offer for sale compounded medications to practitioners or institutional pharmacies for administration to patients in the practitioner’s office or in the institutional facility, provided that the pharmacy does not violate Chapter 8.

Wyo. Bd. of Pharmacy CDS Rules ch. 10 § 3(e) — the prescriber-side prohibition, controlled substances only

Practitioners shall not issue controlled substance prescriptions to an individual practitioner for the purpose of general dispensing to patients.

W.S. § 35-7-1024(a) — the statutory registration cycle, which the rule contradicts

Every person who manufactures, distributes or dispenses any controlled substance within this state or who proposes to engage in the manufacture, distribution or dispensing of any controlled substance within this state, must obtain every two (2) years, on or before July 1, a registration issued by the board in accordance with its rules.

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

The prohibition names the transaction and does not depend on quantityHigh confidence: The rule invalidates the order rather than capping it. A prescription order for office use is not a valid order, full stop — so no volume is small enough to make it one, and no definitional exclusion elsewhere in the rulebook can revive it. That matters because Wyoming does carry minimal-quantity office-use exclusions, and they are about paperwork.
The same two words are compulsory on the outsourcing facility’s labelHigh confidence: An outsourcing facility must label compounded drugs with the statement that they are a compounded drug for office use only, or that they are not for resale. Read the two provisions together and Wyoming is not hostile to office stock at all — it has decided which kind of facility supplies it. For a practice that can reach an outsourcing facility, a state described elsewhere as prohibitive is a routed state rather than a closed one.
Both compounding chapters were repealed on one day, and an express permission died with themHigh confidence: Chapter 13, non-sterile compounding, dated 2014, and chapter 17, sterile compounding, dated 2021, were both repealed on 19 August 2025 in a single rulemaking that also reissued chapter 8 and created chapters 18 and 22. Chapter 13 had contained Wyoming’s only express permission to supply practitioners with compounded medications for administration in the office. It is quoted above as repealed law so a reader who meets it in a secondary source can recognise it, and it may not be relied on.
What replaced them contains no state-drafted standard at allHigh confidence: Chapter 22 is four sections long. It states its authority, its purpose and its scope, and then incorporates USP general chapters 795, 797, 800 and 825 by reference. There is no Wyoming-drafted compounding text left. The chapter also records that the Board considers posting the incorporated material online would infringe copyright, so it may be inspected in person in Cheyenne but not copied.The chapter pins its incorporation twice and the two dates do not match: the general clause names the 2024 edition with chapter dates of 1 May 2024, while each named chapter is pinned to the text as it existed on 26 March 2025. Both readings are on the face of the rule. The Board has proposed an amendment to correct exactly this, and the comment period on it has closed.
The Board’s website and the Board’s rules disagree about whether the 503B licence existsHigh confidence: This one has to be published as the contradiction it is, because either half on its own is false. The rules say resident and non-resident outsourcing facilities shall be licensed as such in this State and renew annually, and the fee chapter prices that licence at $300 a year. The Board’s own licensing page says it does not yet have a separate licence type for outsourcing facilities, that it is working on one, and that in the meantime an entity shipping to individuals may be licensed as a non-resident pharmacy and an entity shipping to facilities or pharmacies as a wholesale distributor. Anyone planning to supply Wyoming should ask the Board which credential it will actually issue.The Board page carries no date. A separate, dated Board licensing document treats the same chapter 8 section as fully operative, which is why this is reported as a live contradiction rather than as an out-of-date page.
The prohibition is asymmetric between the two sides of the transactionHigh confidence: The pharmacy-side rule binds every drug class. The prescriber-side rule does not exist for ordinary legend drugs: the only provision aimed at a prescriber obtaining stock for general dispensing is in the controlled-substances rules. So a Wyoming pharmacy is barred from filling an office-use order for anything, while the matching prohibition on the prescriber reaches controlled substances only.
The minimal-quantity exclusions are paperwork relief, not permissionHigh confidence: Chapter 8 twice excludes the distribution of minimal quantities by a licensed retail pharmacy to a licensed practitioner for office use — once from the definition of a transaction, which is what triggers pedigree documentation, and once from the definition of wholesale distribution, which is what triggers the wholesaler licence. Both tell you what a pharmacy is not. Neither touches chapter 2, which tells a pharmacy what it may not do. A vendor quoting the wholesale exclusion as authority is answering a different question from the one that decides this.
The 503B carve-out is written into the definition of compounding itselfHigh confidence: Wyoming defines compounding to exclude work performed in an FDA-registered outsourcing facility in conformance with federal law. An outsourcing facility operating in Wyoming is therefore not compounding for Pharmacy Act purposes at all, which is why its obligations sit in the wholesale chapter rather than the compounding one — and why looking for them in the compounding chapter finds nothing.
Five in-force rules still point at chapters that no longer existHigh confidence: The institutional pharmacy chapter tells a pharmacy compounding sterile products to comply with chapter 17 in three separate places, and the licensing chapter points at chapter 13 for structural and equipment requirements and at chapter 17 for sterile preparation. All five references survive in rules that are in force; both chapters they point at were repealed. A reader following the current rulebook is directed to requirements that are no longer published anywhere.
A false friend inside chapter 2 that looks like an office-stock pathwayHigh confidence: Chapter 2 provides for an "ancillary drug supply" — a permitted stock of drugs held at a nursing home, hospice, extended care facility or intermediate care facility, where the drugs remain the property of the pharmacy that holds the joint permit, at $25 a year. It is a facility-based emergency supply mechanism and it is not a route to office stock for a medical practice.

Wyoming at a glance

Wyoming office-use compounding summary, reviewed 2026-08-31
Human office use	Not a valid order for a pharmacy; an outsourcing facility must label for office use
Sterile preparations	No state text either way since 19 August 2025; USP chapters incorporated by reference
Quantity cap	None — the order is invalid regardless of quantity
Mandatory label legend	"This is a compounded drug. For office use only" — required of outsourcing facilities
Board reporting	None for office use; pedigree duties sit in the wholesale chapter
Last change	Compounding chapters repealed and replaced 19 August 2025
Governing rule	Wyo. Bd. of Pharmacy Rules ch. 2 § 6(d), with ch. 8 § 7

Receiving 503B office stock in Wyoming

Wyoming is the one state on this site where we cannot tell you with confidence which licence an outsourcing facility will be issued, because the Board and its own rules give different answers. Both are set out here. The receiving practice’s position, by contrast, is stated clearly in the controlled-substances rules and turns on whether it keeps stock.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Wyoming asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inMedium confidence: By rule: a Wyoming outsourcing facility licence, resident or non-resident, renewed annually, at $300 a year, per location, with FDA licensure under section 503(b) and compliance with current good manufacturing practice. Accreditation that the chapter requires of other wholesale licensees is expressly waived for outsourcing facilities. By the Board’s own page: no such licence type exists yet, and an applicant is routed to a non-resident pharmacy licence at $300 or a distributor licence at $275 instead. Ask before applying.
Does your practice need a permit?High confidence: For controlled substances, yes, if it keeps stock. The controlled-substances rules treat an office as exempt from registration only where controlled substances are prescribed but neither administered nor otherwise dispensed there as a regular part of practice, and where no supplies of controlled substances are maintained. A practice holding office stock fails that test on its face.
Administer vs dispenseHigh confidence: Wyoming answers at the order rather than at the act: the pharmacy may not fill an order that is not for one specific patient, so the question of what the practitioner would then do with the stock is never reached through that route. The statutory labelling requirement points the same way, requiring the name of the patient or customer for whom the prescription was made on the dispensed container.
Scheduled (controlled) stockHigh confidence: A Wyoming controlled-substance registration is required, issued by the Board of Pharmacy, with a separate registration per location. Cite the statute rather than the rule for the cycle: the statute requires registration every two years on or before 1 July, while the rule, effective 2014 and never conformed, still describes an annual registration expiring at the end of June.The Attorney General is the statutory Commissioner of Drugs and Substances Control in Wyoming, but the registration itself is administered by the Board of Pharmacy. A reader who follows the title rather than the section will look in the wrong place.

How to check a facility’s credential before you order is set out in how to place an office-use order.

The federal layer still applies

Federal law is a second, independent constraint — a state prohibition is not the only thing standing in the way. 21 U.S.C. § 353a conditions the federal compounding exemptions on a drug being compounded for an identified individual patient on receipt of a valid prescription order. A state rule cannot create a federal safe harbour, and several state rules say so in their own text. The separate federal pathway for non-patient-specific office stock is the 503B outsourcing facility — the differences are set out in 503A vs 503B.

For how Wyoming compares with the other states reviewed, see the state-by-state comparison.

What this page does not establish

Whether Wyoming will issue an outsourcing facility licence is genuinely unsettled, and this page reports both answers rather than choosing one. The rules create the class, require resident and non-resident facilities to hold it and set its fee; the Board’s own licensing page says the class does not yet exist and routes applicants elsewhere. Neither "Wyoming has an outsourcing facility licence" nor "Wyoming has no outsourcing facility licence" is a safe sentence on its own.
Wyoming’s operative compounding requirements are not establishable from any public source. Since 19 August 2025 the entire content of its compounding chapter is the USP general chapters incorporated by reference, and the Board records that it may not publish or copy them and that they may be inspected in person at its offices. So no beyond-use date, batch limit or facility standard can be stated here, and none is.
A practical warning about checking Wyoming’s rules yourself. The Secretary of State’s rules repository serves no rule text to an automated request at all: an address carrying the Board’s own chapter reference number returns "no results", and the document link works only inside a browser session. The rule text quoted on this page was read from those documents, and the citations name the chapter, section, reference number and effective date so you can find them — but there is no durable address we can link you to, and we would rather say that than give you a link that does not work.
Two rulemakings were open when this page was written. The Board’s laws page flags its controlled-substances chapter 10 — the chapter carrying the prescriber-side prohibition — as having proposed revisions; the dated comment notice published beside it, closing 16 October 2026, concerns a different chapter, and the page does not say whether the same deadline applies to chapter 10. The chapter 22 amendment that would fix the two-date defect had closed for comment with no adoption recorded. Neither outcome is known here.
Legislation effective 1 July 2026 amended the Pharmacy Act and directs the Board to make new rules. Those rules were not available when this page was written and are not accounted for in it.
Whether the prescriber’s own licensing board permits obtaining and administering office stock is beyond the scope of this page, which covers the pharmacy side only.
We searched no case law, attorney-general opinions or declaratory rulings for this state, and search engines were unavailable when it was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.